COVID-19 (Coronavirus)

Dan Theodorescu, MD, PhD

PHASE ONE Foundation Distinguished Chair

Director, Cedars-Sinai Cancer

Professor, Surgery

Professor, Pathology and Laboratory Medicine

Dan Theodorescu, MD, PhD

Phone:

310-423-8431

Dan Theodorescu, MD, PhD

PHASE ONE Foundation Distinguished Chair

Director, Cedars-Sinai Cancer

Professor, Surgery

Professor, Pathology and Laboratory Medicine

Dan Theodorescu, MD, PhD, is the director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. From 2010 until 2018, he was director of the University of Colorado Cancer Center and a distinguished university professor. Dr. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as the discovery of new drugs for cancer. Examples include the discovery of genes that regulate tumor growth and metastasis (RhoGDI2, AGL, GON4L), and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, which is being tested in national (SWOG) clinical trials. He also conceptualized the approach and then led the discovery and development of a "first in class" RalGTPase inhibitor as a new therapeutic in cancer. This drug was awarded a U.S. patent and is in commercial development. His laboratory is funded by grants from the NIH-NCI. Dr. Theodorescu has published over 300 articles including articles in Nature, Science, Cancer Cell, PNAS and JCI.

  • Medical School: Queen's University, Ontario, 1986
  • Internship: University of Toronto, 1987
  • Doctorate: University of Toronto, 1993
  • Residency: University of Toronto, 1994
  • Fellowship: Memorial Sloan-Kettering Cancer Center, 1995

English

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.